The pre-clinical team at Merus is looking for an enthusiastic collaborative technician with cell biology skills. The team studies the mechanism of action of our bispecific antibodies and plays an important role in the discovery of ground-breaking new medicines for the treatment of cancer. As a team member you will be part of an international organization where everything you do contributes to our company’s mission: closing in on cancer.
As Technician - Cell Biology, your main tasks and responsibilities will be the following:
Carrying out cell-based assays, including primary cell assays and reporter assays
Culturing mammalian cell lines, both adherent and suspension cells
Carrying out FACS analysis
Developing cell-based assays
Developing research protocols
Documenting laboratory experiments
We are looking for a Technician - Cell Biology with the following knowledge and expertise:
You have a bachelor’s or master’s degree
You have at least 3 years of relevant work experience
You have expertise in mammalian cell culture
You have demonstrable experience with cell-based assays, including flow cytometry
You are organized and detail oriented
You are highly collaborative and work well in teams
You are quality-driven and focused on solutions
We offer a competitive salary and flexible working hours. Our talented international team works in an inspiring area of Utrecht (Utrecht Science Park) in a state-of-the-art facility. We also offer an excellent pension scheme, company bonus, and 30 days’ annual holiday based on a full-time position. We care about team spirit and organize several company events each year. Internal candidates may also apply for this position.
Merus is closing in on cancer:
When hiring new employees, we look for people who will fit in well with the collaborative, rigorous, and entrepreneurial spirit of our company. Working at Merus provides you with opportunities to grow and develop a career that offers both individual and company success. You will have the chance to make an impact within the oncology field by helping to develop antibody therapies that address unmet needs in patients with various types of cancer. We use our proprietary technology platforms to develop innovative multispecific antibodies known as Multiclonics®: full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics®) antibodies that bind to multiple targets. Multiclonics® have features that specifically target the complex mechanisms that drive cancer. Over the last 10 years, we have taken several candidate drugs into clinical trials. Our most advanced cancer drug candidate is zenocutuzumab (Zeno), a Biclonics® antibody that targets HER2 and HER3, and that appears to be particularly effective in cancers driven by a rare gene fusion known as a neuregulin 1 (NRG1) fusion. In a phase 1/2 clinical study in cancer patients with solid tumors harboring such NRG1 fusions – including lung, pancreatic and other types of solid tumors – Zeno has shown encouraging early clinical activity. For more information, please visit www.merus.nl.